Skip to main content

Table 2 Cost savings for PCV13 vs. PCV7 pediatric vaccination in normal and pandemic influenza seasons

From: Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States

Influenza scenario

IPD

Hospitalized pneumonia

Non-Hospitalized pneumonia

Vaccination

Total

Normal season

$ 235 M

$ 509 M

$ 96 M

($ 367 M)

$ 472 M

Pandemic similar to 2009–2010 H1N1

$ 358 M

$ 812 M

$ 213 M

($ 367 M)

$ 1.02 B

  1. IPD, Invasive pneumococcal disease; M, Million; B, Billion.